Prognostic impact of hormone receptor- and HER2-defined subtypes in inflammatory breast cancer treated with high-dose chemotherapy: a retrospective study
暂无分享,去创建一个
F. Bertucci | P. Viens | C. Tarpin | C. Chabannon | E. Charafe-Jauffret | G. Houvenaeghel | A. Gonçalves | J. Boher | E. Lambaudie | R. Sabatier | A. Tallet | J. Extra | C. Lemarié | B. Calmels | M. Resbeut | P. Sfumato | L. Boudin | M. Provansal
[1] X. Xue,et al. Comparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple Negative Breast Cancer , 2016, Journal of Cancer.
[2] J. Lemonnier,et al. UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] K. Friedrich,et al. Impact of breast cancer subtypes and patterns of metastasis on outcome , 2015, Breast Cancer Research and Treatment.
[4] F. Bertucci,et al. [Systemic treatments of inflammatory breast cancer: an overview]. , 2014, Bulletin du cancer.
[5] Isabelle Bedrosian,et al. Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] F. Bertucci,et al. Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] G. Hortobagyi,et al. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] S. Barni,et al. Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients , 2012, Expert opinion on biological therapy.
[9] T. Delozier,et al. Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. , 2012, The Lancet. Oncology.
[10] D. Berry,et al. High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] D. Berry,et al. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] S. Merajver,et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] F. Bertucci,et al. Gene expression profiling of inflammatory breast cancer , 2010, Cancer.
[14] J. Baselga,et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort , 2010, The Lancet.
[15] M. Kiechle,et al. Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] S. Pocock,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.
[17] S. Devesa,et al. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. , 2005, Journal of the National Cancer Institute.
[18] B. Asselain,et al. Dose-intensified chemotherapy and additional Docetaxel may improve inflammatory breast cancer patients outcome over two decades: Results from Institut Curie protocols 1977–1987 and two consecutive French multicenter trials Pegase 02 (1995–96) and Pegase 05 (1997–99) , 2004 .
[19] Y. Yen,et al. Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. , 2004, Journal of Clinical Oncology.
[20] F. Bertucci,et al. Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment , 2004, Bone Marrow Transplantation.
[21] T. Delozier,et al. First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial) , 1999, British Journal of Cancer.
[22] R. Vij,et al. Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] F. Bertucci,et al. High-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer: pathologic response and outcome , 1998, Bone Marrow Transplantation.
[24] B. Teicher,et al. Preclinical studies and clinical correlation of the effect of alkylating dose. , 1988, Cancer research.
[25] E. Frei,et al. Dose: a critical factor in cancer chemotherapy. , 1980, The American journal of medicine.
[26] Giulia Bianchi,et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. , 2012, The Lancet. Oncology.
[27] O. Gluz,et al. [Prognostic and predictive impact of protein expression profiling in high risk breast cancer patients treated with high-dose chemotherapy]. , 2007, Verhandlungen der Deutschen Gesellschaft fur Pathologie.
[28] B. Asselain,et al. Dose-intensified chemotherapy and additional Docetaxel may improve inflammatory breast cancer patients outcome over two decades: Results from Institut Curie protocols 1977-1987 and two consecutive French multicenter trials Pegase 02 (1995-96) and Pegase 05 (1997-99). , 2004, Journal of Clinical Oncology.